ECCO'25 Abstracts

ECCO'25 Abstracts on the JCC Website

ECCO'25 Abstract Book PDF Version

ECCO'25 Abstracts COI Disclosure

ECCO'24 Abstracts

ECCO'24 Abstracts on the JCC Website

ECCO'24 Abstract Book PDF Version

ECCO'24 Abstracts COI Disclosure

Poster presentations: Epidemiology 2021

P603 Patient characteristics and adverse effects in biologic treatment of Crohn’s Disease and Ulcerative Colitis: A nationwide Danish cohort study years 2015-2018.

P604 Evaluation of management heterogeneity and complications of Crohn’s disease in Catalonia. A population quality care study

P605 Development and validation of an objective disability index for Inflammatory Bowel Disease patients (ODIBD)

P606 Adherence to endoscopic surveillance guidelines for advanced lesions and colorectal cancer in Inflammatory Bowel Disease in Spain: a collaborative study of AEG and GETECCU.

P607 The Faroese IBD Study: Update on incidence from 2015-2020 and prevalence from 1960-2020

P608 Inflammatory Bowel Disease (IBD) and immunosuppression do not worsen the prognosis of COVID-19. Results from the ENEIDA Project of GETECCU

P609 Impact of accessibility of medical care and socioeconomic class on outcomes of IBD – a nationwide population study

P610 Fear of COVID-19 among persons with Inflammatory Bowel Disease according to employment status, educational background and residential setting, as compared to persons with other gastrointestinal conditions

P611 Incidence, clinical presentation, and severity of SARS-CoV-2 infection in IBD patients in the second and the third wave of infection

P612 Lower incidence of COVID-19 in patients with Inflammatory Bowel Diseases treated with non-gut-selective biologic therapy: an observational multicentre study.

P613 Social Media Analytics for Inflammatory Bowel Disease – What Are We Missing?

P614 A strategy to solve complexity of physician diagnosis using a mixture of Patient Reports and Provider Reports: A Case Study of Crohn’s Disease Phenotypes

P615 Does smoking really influence the development and the outcomes of Inflammatory Bowel Disease in Asian population? Results from the Taiwanese patients

P616 Sustainability of thiopurines monotherapy in ulcerative colitis: a nationwide analysis from the epi-IIRN cohort

P617 Trends in Pediatric Inflammatory Bowel Disease-attributable direct costs: A Canadian population-based analysis

P618 Treatment outcomes of patients with Crohn’s disease and complex perianal fistula in five European countries: the PREFACE retrospective study

P619 has been withdrawn

P620 Pivoting in a pandemic: The impact of COVID-19 on the provision of care for patients with Inflammatory Bowel Disease – A retrospective study

P621 Lactose intolerance assessed by analysis of genetic polymorphism, breath test and symptoms in patients with inflammatory bowel disease

P622 Comparison of midterm outcomes in Pediatric Crohn’s Disease patients treated with either Exclusive Enteral Nutrition or Corticosteroids around disease diagnosis– a population based study

P623 The impact of SARS-CoV-2 outbreak on the treatment adherence and clinical outcome of patients with inflammatory bowel disease treated with biological agents.

P624 A higher prevalence of human papillomavirus in patients with perianal fistulizing Crohn's disease compared to patients with anorectal fistula without Crohn's disease.

P625 Characteristics of SARS-CoV-2 infection in IBD patients in the second and third wave compared with the first wave and with the data of general population

P626 SARS-CoV-2 seroprevalence in patients with Inflammatory Bowel Disease

P627 Change in urgency among ulcerative colitis patients: Analyses from the SPARC IBD

P628 Risk Factors Associated with Extraintestinal Manifestations in Patients with Inflammatory Bowel Diseases

P629 Rural-urban inequities in Inflammatory Bowel Disease health care access: a population-based retrospective cohort study from a Western Canadian Province

P630 Inflammatory bowel disease in immigrants to Spain: results of the EIIMIGRA study from GETECCU (ENEIDA registry)

P631 Food triggers in inflammatory bowel disease from the patients’ and doctors’ perspective

P632 Is the gender or age of the physician key to a good physician-patient with Inflammatory Bowel Disease relationship?

P633 Clinical epidemiology of Inflammatory Bowel Disease in Lbanon

P634 Trajectories of oral budesonide use in Crohn's disease cohort of Tuscan patients

P635 Assessment of sarcopenia and nutritional status in a cohort of patients with Crohn’s disease

P636 The natural history of COVID-19 in patients with IBD: A nationwide study by the Hellenic Society for the Study of IBD.

P637 Incidence rate and clinical outcome of severe COVID-19 in Inflammatory Bowel Disease patients in a population-based setting

P638 Changes in the management of IBD patients since the onset of COVID-19 pandemic. A path towards the implementation of telemedicine in Spain?

P639 Epidemiology and patient burden of rectovaginal and anovaginal fistulas in patients with Crohn’s disease: A systematic review

P640 Characteristics of elderly onset Inflammatory Bowel Disease in a cohort of Hispanics

P641 Impact of lockdown period due to COVID-19 pandemic in patients with Inflammatory Bowel Disease

P642 Effects of Covid-19 on employment in IBD patients

P643 Patient perspectives and expectations in inflammatory bowel disease: a systematic review

P644 Hospitalization and abdominal surgery rates in CD according to drug-dispensing: a temporal trend analysis from the Brazilian public healthcare national system

P645 Mental health, work presenteeism and exercise in IBD patients

P646 The Loss of Productivity in Employment and Education Associated to Inflammatory Bowel Diseases: A Pilot Study of the Patient’s Perception

P647 Awareness, knowledge and use of mesenchymal stem cells – a global survey among gastroenterologists and colorectal surgeons

P648 Physical and mental health during COVID-19 quarantine in adolescents with chronic immunocompromised conditions and inflammatory bowel disease

P649 Ulcerative Colitis Narrative Japanese survey: Identifying gaps between patient and healthcare professional perspectives on communication and disease management to optimise patient care

P650 A trend to higher adoption of mesalazine suppository use for UC patients in 15 European countries

P651 Diagnostic delay, effectiveness and safety outcomes in a real-world cohort of patients with Crohn’s disease: data from administrative databases in Tuscany, Italy

P652 Treatment patterns in patients receiving outpatient care for inflammatory bowel disease in Russian Federation

P653 Rheumatic extraintestinal manifestations in ulcerative colitis : Prevalence and predictive factors

P654 Prevalence of Inflammatory Bowel Disease in young Greek Army male recruits from 2006 to 2018: a thirteen-year retrospective study from a tertiary center

P655 Insulin Resistance Prevalence is Not Increased in Patients with Inflammatory Bowel Disease: a case-control study

P656 Epidemiology and outcomes associated with local surgical and intersphincteric ligation procedures for complex cryptoglandular fistulas: A systematic literature review

P657 Acceptability of a COVID-19 vaccine among cohort of Croatian IBD patients treated in tertiary IBD centre

P658 Is vitamin D deficiency related to fat malabsorption or inflammation in Inflammatory Bowel Disease? Preliminary results from the Fat-D study

P659 Colonoscopic screening of symptomatic patients suggests an emerging inflammatory bowel disease (IBD) in urban and rural south India

P660 The impact of COVID-19 on the provision of care for patients with Inflammatory Bowel Disease: A cross sectional survey

P661 Radon exposure and inflammatory bowel disease in a radon prone area

P662 A retrospective claims analysis on the prevalence and incidence of ulcerative colitis in Germany and the frequency of advanced therapy use

P663 Long-term follow up in IBD: 10-year observational study of a UK IBD cohort.

P664 Adherence to mesalazine and identification of patients with ulcerative colitis in healthcare administrative databases of Tuscany (Italy)

P665 Cardiovascular risk profile in chronic auto-inflammatory diseases: a cross-sectional single center study

P666 Frequency and outcome of SARS-CoV2 infection in patients with inflammatory bowel disease on different biological therapy

P667 Characterization of a large Hispanic cohort with Inflammatory Bowel Disease across a 25-year span

P668 Does biotin deficiency play a role in the pathogenesis of Inflammatory Bowel Disease? Preliminary results of a cross-sectional study